141 related articles for article (PubMed ID: 9359497)
1. Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy.
Zhang MJ; Baccarani M; Gale RP; McGlave PB; Atkinson K; Champlin RE; Dicke KA; Giralt S; Gluckman E; Goldman JM; Klein JP; Herzig RH; Masaoka T; O'Reilly RJ; Rozman C; Rowlings PA; Sobocinski KA; Speck B; Zwaan FE; Horowitz MM
Br J Haematol; 1997 Oct; 99(1):23-9. PubMed ID: 9359497
[TBL] [Abstract][Full Text] [Related]
2. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.
Gale RP; Hehlmann R; Zhang MJ; Hasford J; Goldman JM; Heimpel H; Hochhaus A; Klein JP; Kolb HJ; McGlave PB; Passweg JR; Rowlings PA; Sobocinski KA; Horowitz MM
Blood; 1998 Mar; 91(5):1810-9. PubMed ID: 9473250
[TBL] [Abstract][Full Text] [Related]
3. Five year leukaemia-free survival of 72% and 77% for early stage acute and chronic myeloid leukaemia treated by HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K; Dodds A; Concannon A; Milliken S
Aust N Z J Med; 1996 Feb; 26(1):54-8. PubMed ID: 8775529
[TBL] [Abstract][Full Text] [Related]
4. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
Goldman JM; Szydlo R; Horowitz MM; Gale RP; Ash RC; Atkinson K; Dicke KA; Gluckman E; Herzig RH; Marmont A
Blood; 1993 Oct; 82(7):2235-8. PubMed ID: 8400272
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse.
Savage DG; Szydlo RM; Chase A; Apperley JF; Goldman JM
Br J Haematol; 1997 Oct; 99(1):30-5. PubMed ID: 9359498
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Gratwohl A; Hermans J; Goldman JM; Arcese W; Carreras E; Devergie A; Frassoni F; Gahrton G; Kolb HJ; Niederwieser D; Ruutu T; Vernant JP; de Witte T; Apperley J
Lancet; 1998 Oct; 352(9134):1087-92. PubMed ID: 9798583
[TBL] [Abstract][Full Text] [Related]
8. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.
Giralt S; Szydlo R; Goldman JM; Veum-Stone J; Biggs JC; Herzig RH; Klein JP; McGlave PB; Schiller G; Gale RP; Rowlings PA; Horowitz MM
Blood; 2000 Jan; 95(2):410-5. PubMed ID: 10627443
[TBL] [Abstract][Full Text] [Related]
9. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
[TBL] [Abstract][Full Text] [Related]
10. Identical-twin bone marrow transplants for leukemia.
Gale RP; Horowitz MM; Ash RC; Champlin RE; Goldman JM; Rimm AA; Ringdén O; Stone JA; Bortin MM
Ann Intern Med; 1994 Apr; 120(8):646-52. PubMed ID: 8135448
[TBL] [Abstract][Full Text] [Related]
11. Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning.
Cullis JO; Schwarer AP; Hughes TP; Hows JM; Franklin I; Morgenstern G; Goldman JM
Br J Haematol; 1992 Jan; 80(1):33-9. PubMed ID: 1536808
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
Litzow MR; Pérez WS; Klein JP; Bolwell BJ; Camitta B; Copelan EA; Gale RP; Giralt SA; Keating A; Lazarus HM; Marks DI; McCarthy PL; Miller CB; Milone G; Prentice HG; Russell JA; Schultz KR; Trigg ME; Weisdorf DJ; Horowitz MM
Br J Haematol; 2002 Dec; 119(4):1115-24. PubMed ID: 12472596
[TBL] [Abstract][Full Text] [Related]
13. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.
Davies SM; DeFor TE; McGlave PB; Miller JS; Verfaillie CM; Wagner JE; Weisdorf DJ
Am J Med; 2001 Apr; 110(5):339-46. PubMed ID: 11286947
[TBL] [Abstract][Full Text] [Related]
14. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase.
Gale RP; Park RE; Dubois RW; Herzig GP; Hocking WG; Horowitz MM; Keating A; Kempin S; Linker CA; Schiffer CA; Wiernik PH; Weisdorf DJ; Rai KR
Leuk Res; 1999 Sep; 23(9):817-26. PubMed ID: 10475621
[TBL] [Abstract][Full Text] [Related]
15. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
16. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome.
Beelen DW; Graeven U; Elmaagacli AH; Niederle N; Kloke O; Opalka B; Schaefer UW
Blood; 1995 May; 85(10):2981-90. PubMed ID: 7742558
[TBL] [Abstract][Full Text] [Related]
17. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.
Arcese W; Goldman JM; D'Arcangelo E; Schattenberg A; Nardi A; Apperley JF; Frassoni F; Aversa F; Prentice HG; Ljungman P
Blood; 1993 Nov; 82(10):3211-9. PubMed ID: 7693042
[TBL] [Abstract][Full Text] [Related]
18. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
19. Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.
J Clin Oncol; 1999 Jun; 17(6):1858-68. PubMed ID: 10561226
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
Gratwohl A; Hermans J; Niederwieser D; Frassoni F; Arcese W; Gahrton G; Bandini G; Carreras E; Vernant JP; Bosi A
Bone Marrow Transplant; 1993 Nov; 12(5):509-16. PubMed ID: 8298562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
